Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 6/2021

07.01.2021 | Original Article

Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to Pneumocystis pneumonia

verfasst von: Gaston Burghi, Lucie Biard, Antoine Roux, Sandrine Valade, Florence Robert-Gangneux, Samia Hamane, Daniéle Maubon, Anne Debourgogne, Soléne Le Gal, Fréderic Dalle, Marion Leterrier, Dominique Toubas, Christelle Pomares, Anne Pauline Bellanger, Julie Bonhomme, Antoine Berry, Xavier Iriart, Isabelle Durand-Joly, Denis Magne, Denis Pons, Christophe Hennequin, Eric Maury, Elie Azoulay, Virginie Lemiale

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

In the non-AIDS group, several underlying conditions and immune defects could lead to different PCP presentations. This study compared PCP presentation and outcome according to the underlying disease. A secondary analysis of a previously published prospective observational study including 544 PCP patients was done. Only non-AIDS patients were included. Underlying disease was defined as chronic lymphocytic leukemia (CLL), organ transplantation, solid cancer, allogeneic hematopoietic stem cell transplant (AHSCT), other hematological diseases, and immunosuppressive treatment. Clinical characteristics and outcomes were compared between groups. Multiple correspondent analyses compared clinical characteristics at diagnosis. Day 30 mortality was analyzed. Three hundred and twenty-one patients were included in the study. The underlying diseases were hematological malignancy (n = 75), AHSCT (n = 14), CLL (n = 19), solid organ transplant (n = 94), solid tumor (n = 39), and immunosuppressive treatment (n = 57). Compared with other underlying diseases, PCP related to CLL was closer to PCP related to AIDS presentation (long duration of symptoms before diagnosis, high level of dyspnea, and low oxygen saturation at diagnosis). Day 30 mortality was associated with underlying disease, oxygen flow, and shock at ICU admission. PCP presentations may vary according to the underlying reason for immunosuppression. Response to treatment and adjuvant steroid therapy should be analyzed regarding this result.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bollée G, Sarfati C, Thiéry G, Bergeron A, de Miranda S, Menotti J et al (2007) Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest 132:1305–1310CrossRef Bollée G, Sarfati C, Thiéry G, Bergeron A, de Miranda S, Menotti J et al (2007) Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest 132:1305–1310CrossRef
2.
Zurück zum Zitat Gonzalez Santiago TM, Wetter DA, Kalaaji AN, Limper AH, Lehman JS (2016) Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis. Int J Dermatol 55:823–830CrossRef Gonzalez Santiago TM, Wetter DA, Kalaaji AN, Limper AH, Lehman JS (2016) Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis. Int J Dermatol 55:823–830CrossRef
3.
Zurück zum Zitat Matsumoto T, Fujita M, Hirano R, Sasaki T, Watanabe K (2019) Risk factors for pneumocystis pneumonia onset in HIV-negative patients treated with high-dose systemic corticosteroids. Infect Dis (Lond) 51:305–307CrossRef Matsumoto T, Fujita M, Hirano R, Sasaki T, Watanabe K (2019) Risk factors for pneumocystis pneumonia onset in HIV-negative patients treated with high-dose systemic corticosteroids. Infect Dis (Lond) 51:305–307CrossRef
4.
Zurück zum Zitat Park SY, Jung JH, Kwon H, Shin S, Kim YH, Chong Y et al (2020) Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: a case-control study. Transpl Infect Dis 22(2):e13245CrossRef Park SY, Jung JH, Kwon H, Shin S, Kim YH, Chong Y et al (2020) Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: a case-control study. Transpl Infect Dis 22(2):e13245CrossRef
5.
Zurück zum Zitat Watanabe H, Kitahara Y, Murakami Y, Nihashi F, Matsushima S, Eifuku T et al (2020) Pneumocystis jirovecii pneumonia in a patient with breast cancer receiving neoadjuvant dose-dense chemotherapy. Intern Med 59:987–990CrossRef Watanabe H, Kitahara Y, Murakami Y, Nihashi F, Matsushima S, Eifuku T et al (2020) Pneumocystis jirovecii pneumonia in a patient with breast cancer receiving neoadjuvant dose-dense chemotherapy. Intern Med 59:987–990CrossRef
6.
Zurück zum Zitat Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A et al (2014)Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 20:1490–1497CrossRef Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A et al (2014)Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 20:1490–1497CrossRef
7.
Zurück zum Zitat Monnet X, Vidal-Petiot E, Osman D, Hamzaoui O, Durrbach A, Goujard C et al (2008) Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care 12:R28CrossRef Monnet X, Vidal-Petiot E, Osman D, Hamzaoui O, Durrbach A, Goujard C et al (2008) Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care 12:R28CrossRef
8.
Zurück zum Zitat Festic E, Gajic O, Limper AH, Aksamit TR (2005) Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 128:573–579CrossRef Festic E, Gajic O, Limper AH, Aksamit TR (2005) Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 128:573–579CrossRef
9.
Zurück zum Zitat Gassner FJ, Weiss L, Geisberger R, Hofbauer JP, Egle A, Hartmann TN et al (2011) Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. Cancer Immunol Immunother 60:75–85CrossRef Gassner FJ, Weiss L, Geisberger R, Hofbauer JP, Egle A, Hartmann TN et al (2011) Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. Cancer Immunol Immunother 60:75–85CrossRef
10.
Zurück zum Zitat Thomas CF, Limper AH (2007) Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 5:298–308CrossRef Thomas CF, Limper AH (2007) Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 5:298–308CrossRef
11.
Zurück zum Zitat Werbel WA, Ison MG, Angarone MP, Yang A, Stosor V (2018) Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation. Transpl Infect Dis 20:e12876CrossRef Werbel WA, Ison MG, Angarone MP, Yang A, Stosor V (2018) Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation. Transpl Infect Dis 20:e12876CrossRef
12.
Zurück zum Zitat Pagano L, Fianchi L, Leone G (2006) Fungal pneumonia due to molds in patients with hematological malignancies. J Chemother 18:339–352CrossRef Pagano L, Fianchi L, Leone G (2006) Fungal pneumonia due to molds in patients with hematological malignancies. J Chemother 18:339–352CrossRef
13.
Zurück zum Zitat Tasaka S, Tokuda H (2012) Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother 18:793–806CrossRef Tasaka S, Tokuda H (2012) Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother 18:793–806CrossRef
14.
Zurück zum Zitat Gaborit BJ, Tessoulin B, Lavergne R-A, Morio F, Sagan C, Canet E et al (2019) Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study. Ann Intensive Care 9:131CrossRef Gaborit BJ, Tessoulin B, Lavergne R-A, Morio F, Sagan C, Canet E et al (2019) Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study. Ann Intensive Care 9:131CrossRef
15.
Zurück zum Zitat Thomas CF, Limper AH (2004) Pneumocystis pneumonia. N Engl J Med 350:2487–2498CrossRef Thomas CF, Limper AH (2004) Pneumocystis pneumonia. N Engl J Med 350:2487–2498CrossRef
16.
Zurück zum Zitat Nandakumar V, Hebrink D, Jenson P, Kottom T, Limper AH (2017) Differential macrophage polarization from Pneumocystis in immunocompetent and immunosuppressed hosts: potential adjunctive therapy during pneumonia. Infect Immun 85(3):e00939-16CrossRef Nandakumar V, Hebrink D, Jenson P, Kottom T, Limper AH (2017) Differential macrophage polarization from Pneumocystis in immunocompetent and immunosuppressed hosts: potential adjunctive therapy during pneumonia. Infect Immun 85(3):e00939-16CrossRef
17.
Zurück zum Zitat Moon SM, Kim T, Sung H, Kim M-N, Kim S-H, Choi S-H et al (2011) Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 55:4613–4618CrossRef Moon SM, Kim T, Sung H, Kim M-N, Kim S-H, Choi S-H et al (2011) Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 55:4613–4618CrossRef
18.
Zurück zum Zitat Wieruszewski PM, Barreto JN, Frazee E, Daniels CE, Tosh PK, Dierkhising RA et al (2018) Early corticosteroids for Pneumocystis pneumonia in adults without HIV are not associated with better outcome. Chest 154:636–644CrossRef Wieruszewski PM, Barreto JN, Frazee E, Daniels CE, Tosh PK, Dierkhising RA et al (2018) Early corticosteroids for Pneumocystis pneumonia in adults without HIV are not associated with better outcome. Chest 154:636–644CrossRef
19.
Zurück zum Zitat Borcoman E, Dupont A, Mariotte E, Doucet L, Joseph A, Chermak A et al (2020) One-year survival in patients with solid tumours discharged alive from the intensive care unit after unplanned admission: a retrospective study. J Crit Care 57:36–41CrossRef Borcoman E, Dupont A, Mariotte E, Doucet L, Joseph A, Chermak A et al (2020) One-year survival in patients with solid tumours discharged alive from the intensive care unit after unplanned admission: a retrospective study. J Crit Care 57:36–41CrossRef
20.
Zurück zum Zitat Fishman JA, Gans H (2019) AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl 33:e13587CrossRef Fishman JA, Gans H (2019) AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl 33:e13587CrossRef
Metadaten
Titel
Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to Pneumocystis pneumonia
verfasst von
Gaston Burghi
Lucie Biard
Antoine Roux
Sandrine Valade
Florence Robert-Gangneux
Samia Hamane
Daniéle Maubon
Anne Debourgogne
Soléne Le Gal
Fréderic Dalle
Marion Leterrier
Dominique Toubas
Christelle Pomares
Anne Pauline Bellanger
Julie Bonhomme
Antoine Berry
Xavier Iriart
Isabelle Durand-Joly
Denis Magne
Denis Pons
Christophe Hennequin
Eric Maury
Elie Azoulay
Virginie Lemiale
Publikationsdatum
07.01.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 6/2021
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-020-04118-w

Weitere Artikel der Ausgabe 6/2021

European Journal of Clinical Microbiology & Infectious Diseases 6/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.